Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Consumer prices rose 0.3% in December, higher than expected, pushing the annual rate to 3.4%
CNBC’s Rick Santelli joins ‘Squawk Box’ to break down December’s CPI data.
Options Action: Bullish bets on Intel
Kevin Kelly, Kelly Intelligence CEO, joins the Options Action traders to talk Intel trading.
CVS to close ‘select’ pharmacies in Target stores starting in February
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Bertha Coombs joins ‘Closing Bell’ to report on the announcement from CVS on their plan to close select pharmacies inside Target locations beginning in February.
SEC’s X page hack ‘not a prank’, was ‘designed to make some money’: Silverado Policy’s Alperovitch
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dmitri Alperovitch, Silverado Policy executive chairman, joins ‘Fast Money’ to talk about the SEC’s page on ‘X’ being hacked and the implications of the hack on the bitcoin market. 05:03 Tue, Jan 9 20246:10 PM EST
The coronavirus pandemic has caused a surge in demand for contactless payments, accelerating the shift from cash to digital options
The Covid-19 pandemic is expected to cause a drastic decline in cash usage due to the risk of contamination. “Over the past six to eight months, we’ve seen the use of cash decline even further, and that’s a trend I think that we’re going to see continue,” said Jodie Kelley, CEO of Electronic Transactions Association….
Google to layoff hundreds as big tech layoffs continue in 2024
© 2024 CNBC LLC. All Rights Reserved. A Division of NBCUniversal Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Market Data Terms of Use and Disclaimers Data also provided by
